Korean College of Rheumatology Biologics and Targeted Therapy Registry

Recruiting now

Conditions studied: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis

In brief

We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving biologics or targeted synthetic DMARDs. As this registry is to observe the "real world" use of anti-rheumatic treatments under routine clinical practice, no hypothesis to prove is planned.

Key facts

Study ID

NCT01965132

Run by

Seoul National University Hospital

People needed

10000

Starts

2012-12-01

Expected to finish

2030-06-30

Last updated by the study team

2024-04-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients diagnosed with RA, AS or PsA
• RA deemed by their rheumatologist to require treatment with a biologic or targeted synthetic DMARDs or a conventional DMARD(s)
• AS or PsA patients who are to initiate, restart or switch to a biologic agent or a targeted synthetic DMARD
• Patients who provide a written consent of participating in this registry (data collection and review).

You may not qualify if…

• RA, AS, PsA patients who are already on biologics or targeted synthetic DMARDs upon screening

Where it is running

• Seoul Metropolitan Government-Seoul National University Boramae Medical Center — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.